Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Suspended 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Classical hematology 2

Conditions

Lung Neoplasms 84Prostatic Neoplasms 73Leukemia, Myeloid, Acute 73Carcinoma, Non-Small-Cell Lung 61Neoplasm Metastasis 60Breast Neoplasms 56Multiple Myeloma 47Colorectal Neoplasms 47Pancreatic Neoplasms 43Carcinoma, Renal Cell 36Myelodysplastic Syndromes 35Melanoma 35Ovarian Neoplasms 33Leukemia, Lymphocytic, Chronic, B-Cell 30Triple Negative Breast Neoplasms 28Glioblastoma 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma, Large B-Cell, Diffuse 26Urinary Bladder Neoplasms 25Lymphoma 23Squamous Cell Carcinoma of Head and Neck 22Burkitt Lymphoma 22Fallopian Tube Neoplasms 21Glioma 20Carcinoma, Hepatocellular 20Brain Neoplasms 18Mouth Neoplasms 17Lymphoma, Non-Hodgkin 17Leukemia, Biphenotypic, Acute 17Endometrial Neoplasms 17

Interventions

fludarabine phosphate 60Cyclophosphamide 60Busulfan 43Cyclosporine 41Mycophenolic Acid 40Peripheral Blood Stem Cell Transplantation 39Cytarabine 36Whole-Body Irradiation 34Antilymphocyte Serum 29Filgrastim 26Tacrolimus 24Methotrexate 24fludarabine 23Cord Blood Stem Cell Transplantation 22Radiotherapy 21Melphalan 20Etoposide 18Methylprednisolone 15Azacitidine 14Granulocyte Colony-Stimulating Factor 13Idarubicin 12Daunorubicin 11Thiotepa 10sargramostim 8Cyclosporins 8Clofarabine 7Arsenic Trioxide 7Transplantation 6Topotecan 6Mitoxantrone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Anemia, Refractory, with Excess of Blasts × Specimen Handling × Clear all
NCT03816319 2026-05-18

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡